Minzasolmin

UCB presented 8 scientific abstracts at AD/PD 2025, including subgroup analysis of bepranemab's TOGETHER trial for Alzheimer's disease, the first anti-tau therapy showing clinical efficacy.

Inhibikase Therapeutics discontinues development of risvodetinib for Parkinson's disease after Phase II trial fails to show significant efficacy despite meeting safety endpoints.

The Asia-Pacific region leads in Parkinson's disease clinical trials, accounting for 44% of global trials, with China having the majority share since 2019.

Genentech's prasinezumab Phase IIb PADOVA study in early-stage Parkinson's missed its primary endpoint of delaying motor progression.

UCB's minzasolmin, an oral alpha-synuclein misfolding inhibitor, did not meet primary or secondary endpoints in the Phase 2 ORCHESTRA trial for early Parkinson's.